3,5-dipentadecyloxybenzamidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3,5-dipentadecyloxybenzamidine
• 英文别名: 3,5-di(pentadecoxy)benzenecarboximidamide
• 化学式: C₃₇H₆₈N₂O₂
• 分子量: 572.959
• InChiKey: BAZNDQYDBLAZTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.2
• 重原子数：
  41
• 可旋转键数：
  31
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  68.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  溴代十五烷 在 盐酸 、 氨 、 potassium carbonate 作用下， 以 氯仿 、 丙酮 、 苯 为溶剂， 反应 6.17h， 生成 3,5-dipentadecyloxybenzamidine
  参考文献：
  名称：

  COATING COMPOSITION AND MEDICAL DEVICE

  摘要：

  公开号：

  EP2954908B1

文献信息

• LIPOSOMES
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP1044679A1

  公开（公告）日：2000-10-18

  This invention provides a liposome having a drug included therein, which has active targeting property and ensured stability in blood and can be used effectively in the diagnosis and/or treatment of diseases, particularly renal diseases, that accompany production of proteoglycan, comprising (1) a basic compound which takes positive charge within a physiological pH range, (2) a lipid derivative of a hydrophilic polymer and (3) a lipid which constitutes the liposome, as its membrane constituting components, wherein their constituting ratios are from 1 to 20 mol% of (1) based on (3) and from 0.2 to 5 mol% of (2) based on the total of (1) and (3).

  本发明提供了一种含有药物的脂质体，该脂质体具有活性靶向性，并确保在血液中的稳定性，可有效用于诊断和/或治疗伴随蛋白多糖产生的疾病，特别是肾脏疾病、包括(1)在生理 pH 值范围内带正电荷的碱性化合物，(2)亲水性聚合物的脂质衍生物和(3)构成脂质体的脂质，作为其膜构成成分，其中它们的构成比例为(1)占(3)的 1 至 20 摩尔%，(2)占(3)的 0.2至5 摩尔%的(2)，以(1)和(3)的总和为基准。
• IRINOTECAN PREPARATION
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP1752150A1

  公开（公告）日：2007-02-14

  Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan formulation including a closed vesicle formed by a lipid membrane, in which irinotecan and/or a salt thereof is encapsulated at a concentration of at least 0.07 mol/mol (drug mol/membrane total lipid mol). There is an ion gradient between an inner aqueous phase and an outer aqueous phase in the irinotecan formulation. The closed vesicle is preferably liposome, in which only the outer surface of the liposome is preferably modified with a surface-modifying agent containing a hydrophilic polymer.

  本发明提供了一种伊立替康制剂，与传统已知的伊立替康脂质体制剂相比，该制剂能够在封闭的囊泡载体中以高浓度支持伊立替康和/或其盐，并通过显著提高在血液中的滞留性而长期存在于血液中。也就是说，伊立替康制剂包括由脂质膜形成的封闭囊泡，其中封装的伊立替康和/或其盐的浓度至少为 0.07 摩尔/摩尔（药物摩尔/膜总脂质摩尔）。在伊立替康制剂中，内水相和外水相之间存在离子梯度。封闭的囊泡最好是脂质体，其中只有脂质体的外表面最好用含有亲水性聚合物的表面修饰剂进行修饰。
• Liposome
  申请人：Terumo Kabushiki Kaisha

  公开号：US20030211142A1

  公开（公告）日：2003-11-13

  This invention provides a liposome having a drug included therein, which has active targeting property and ensured stability in blood and can be used effectively in the diagnosis and/or treatment of diseases, particularly renal diseases, that accompany production of proteoglycan, comprising (1) a basic compound which takes positive charge within a physiological pH range, (2) a lipid derivative of a hydrophilic polymer and (3) a lipid which constitutes the liposome, as its membrane constituting components, wherein their constituting ratios are from 1 to 20 mol % of (1) based on (3) and from 0.2 to 5 mol % of (2) based on the total of (1) and (3).

  本发明提供了一种含有药物的脂质体，该脂质体具有活性靶向性，并确保在血液中的稳定性，可有效用于诊断和/或治疗伴随蛋白多糖产生的疾病，特别是肾脏疾病、包括(1)在生理 pH 值范围内带正电荷的碱性化合物，(2)亲水性聚合物的脂质衍生物和(3)构成脂质体的脂质，作为其膜构成成分，其中它们的构成比例为：(1)占(3)的 1 至 20 摩尔%，(2)占(3)的 0.以(1)和(3)的总和为基准，(2)的比例为 0.2 至 5 摩尔%。
• Stable Liposomes for Targeted Drug Delivery
  申请人：Terumo Kabushiki Kaisha

  公开号：EP1044679B1

  公开（公告）日：2012-12-26
• LIPOSOME PREPARATION
  申请人：Terumo Kabushiki Kaisha

  公开号：EP1731172B1

  公开（公告）日：2013-06-05